摘要
目的探讨盐酸安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌的临床疗效及安全性。方法选择2019年1月至2020年7月在淮北市人民医院就诊的70例至少接受过2种系统性治疗后进展或无法耐受的晚期非小细胞肺癌患者,采用随机数字表法,分为对照组(予以盐酸安罗替尼治疗)与试验组(予以盐酸安罗替尼联合替吉奥治疗),每组35例。对比两组患者治疗效果及不良反应情况的差异。结果试验组患者客观缓解率为37.14%,疾病控制率为82.86%,均高于对照组(P<0.05)。试验组患者中位无进展生存期为7.3个月,高于对照组(P<0.05),但两组的中位总生存期差异无统计学意义(P>0.05)。试验组患者胃肠道反应(51.42%)、骨髓抑制(60.00%)、乏力(62.86%)等不良反应发生率高于对照组(P<0.05),其余不良反应大致相当(P>0.05)。两组患者不良反应均以Ⅰ~Ⅱ级为主,总体可控。结论盐酸安罗替尼联合替吉奥二线后治疗晚期非小细胞肺癌疗效明显,安全性可控。
Objective To investigate the clinical efficacy and safety of anlotinib hydrochloride combined with S-1 in the treatment of second-line advanced non-small cell lung cancer.Methods From January 2019 to July 2020,70 patients with advanced non-small cell lung cancer who developed or could not tolerate after receiving at least two kinds of systematic treatment were selected from Huaibei People’s Hospital.The 35 patients were randomly selected as the control groupand treated with anlotinib hydrochloride.The other 35 patients were set as the experimental group and treated with arotinib hydrochloride combined with S-1.The treatment effect and adverse reactions of the two groups were compared.Results The objective response rate(37.14%)and disease control rate(82.86%)of the experimental group were higher than those of the control group(P<0.05).The progression-free survival time(7.3 months)of the experimental group was higher than that of the control group(P<0.05),but there was no significant difference in the overall survival time between the two groups(P>0.05).The adverse reactions of the two groups were mainly gradeⅠ~Ⅱ,but it could be controlled.The incidence of gastrointestinal reaction(51.42%),myelosuppression(60.00%)and fatigue(62.86%)in the experimental group was higher than that in the control group(P<0.05),and the other adverse reactions were similar(P>0.05).Conclusion The second-line treatment of advanced non-small cell lung cancer with anlotinib hydrochloride combined with S-1 is effective and safe.
作者
王亚
李心忠
姜松龄
张雷
刘群
施舒瑜
牛林军
WANG Ya;LI Xinzhong;JIANG Songling;ZHANG Lei;LIU Qun;SHI Shuyu;NIU Linjun(Department of Oncology,Huaibei People’s Hospital,Huaibei 235000,China)
出处
《安徽医学》
2022年第1期36-40,共5页
Anhui Medical Journal
基金
淮北市科技计划项目(项目编号:rj201818)
白求恩•医学科学研究基金项目(项目编号:B19065ET)。
